# Presolicitation Notice - BARDA Vaccine Medical Countermeasures for Pandemic Influenza Preparedness & Response

Canonical: https://abierto.us/opportunities/75a50126r00001rfppresolnoticenpivs2027

- Solicitation number: 75A50126R00001_RFP_PreSolNotice_NPIVS-2027
- Notice type: Presolicitation
- Status: Closed. Deadline was August 15, 2026 at 5:00 PM EDT
- Department: Department of Health and Human Services
- Agency: Office of Assistant Secretary for Preparedness and Response
- Contracting office: Barda - Aspr / Daappo / Barda DCMA (75A501)
- NAICS: 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Product or service code: AN12 Health R&D Services; Health Care Services; Applied Research
- Place of performance: Washington, District of Columbia
- First posted: July 30, 2026
- Last posted: July 30, 2026
- SAM.gov: https://sam.gov/workspace/contract/opp/7f2d0909120749a39c61c64ff933f1a6/view

## Description

**Description:** BARDA seeks Contractor(s) to support the continuation of the Vaccine MCMs for Pandemic Influenza Preparedness and Response Program.

Contractors will furnish all the necessary services, qualified personnel, materials, supplies, equipment and facilities (U.S. facilities preferred) not otherwise provided by the USG as needed to provide MCMs, such as vaccines, antigens, and adjuvants, for pandemic preparedness and response or as required in response to a public health emergency; produce antigen and vaccines against influenza virus or other viruses with pandemic potential as required by BARDA; produce antigens, adjuvants, and/or vaccines to support USG efforts to further improve influenza vaccines (for which feasibility data is available); and support rapid regulatory decisions and manufacturing readiness by generating and submitting to FDA all relevant data (e.g., analytical, nonclinical, clinical, and/or chemistry, manufacturing, and controls (CMC)), including data generated during interpandemic periods.

**Mandatory Qualification Requirements:** To be eligible for award, the Offeror must produce vaccines against influenza and influenza strains with pandemic potential; must demonstrate a successful experience in the manufacturing of influenza vaccine by: Holding a U.S. influenza vaccine license; or Have developed an influenza vaccine as evidenced by: a.Submission of a BLA for seasonal or pandemic influenza vaccine Please see attachment to this presolicitation notice for further important information.

## Publications

- July 30, 2026: Presolicitation, due August 15, 2026 at 5:00 PM EDT. Notice 7f2d0909120749a39c61c64ff933f1a6. https://sam.gov/workspace/contract/opp/7f2d0909120749a39c61c64ff933f1a6/view

## Points of contact

- Laura Saddison, Laura.Saddison@hhs.gov

---
Source: SAM.gov Contract Opportunities bulk extract. Confirm deadlines on SAM.gov before responding. Cite https://abierto.us/opportunities/75a50126r00001rfppresolnoticenpivs2027.